Your browser doesn't support javascript.
loading
Probing Biased Signaling in Chemokine Receptors.
Amarandi, Roxana-Maria; Hjortø, Gertrud Malene; Rosenkilde, Mette Marie; Karlshøj, Stefanie.
Afiliación
  • Amarandi RM; Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark; Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, Iasi, Romania.
  • Hjortø GM; Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
  • Rosenkilde MM; Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
  • Karlshøj S; Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark. Electronic address: stefanieth@sund.ku.dk.
Methods Enzymol ; 570: 155-86, 2016.
Article en En | MEDLINE | ID: mdl-26921946
ABSTRACT
The chemokine system mediates leukocyte migration during homeostatic and inflammatory processes. Traditionally, it is described as redundant and promiscuous, with a single chemokine ligand binding to different receptors and a single receptor having several ligands. Signaling of chemokine receptors occurs via two major routes, G protein- and ß-arrestin-dependent, which can be preferentially modulated depending on the ligands or receptors involved, as well as the cell types or tissues in which the signaling event occurs. The preferential activation of a certain signaling pathway to the detriment of others has been termed signaling bias and can accordingly be grouped into ligand bias, receptor bias, and tissue bias. Bias has so far been broadly overlooked in the process of drug development. The low number of currently approved drugs targeting the chemokine system, as well as the broad range of failed clinical trials, reflects the need for a better understanding of the chemokine system. Thus, understanding the character, direction, and consequence of biased signaling in the chemokine system may aid the development of new therapeutics. This review describes experiments to assess G protein-dependent and -independent signaling in order to quantify chemokine system bias.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Receptores de Quimiocina / Biología Molecular Límite: Animals / Humans Idioma: En Revista: Methods Enzymol Año: 2016 Tipo del documento: Article País de afiliación: Rumanía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Receptores de Quimiocina / Biología Molecular Límite: Animals / Humans Idioma: En Revista: Methods Enzymol Año: 2016 Tipo del documento: Article País de afiliación: Rumanía